Switzerland· 58665001
Actilyse Cathflo 2mg, Pulver zur Herstellung einer Injektionslösung
A alteplase product, registered in Switzerland by Boehringer Ingelheim (Schweiz) GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Alteplase is registered in 14 of 19 countries.
Countries holding a registration under ATC B01AD02 (alteplase), each read from that country’s own register.
- This record: Switzerland
- 8 of them publish a price we can compare per daily dose
Alteplase · ATC B01AD02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alteplase costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alteplase · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- FI Finland$2204.37
The record
At a glance
- Manufacturer
- Boehringer Ingelheim (Schweiz) GmbH
- Country
- Switzerland (CH)
- ATC code
- B01AD02
- ATC class
- Alteplase
- Defined daily dose
- 0.1 g, P
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
146 interactions on record for alteplase.
Graded by severity as the source publishes them — 49 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alteplase · interactions on record
146 records
- 49 severe
- 97 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B01AD02
Alteplase, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fc285919-2d06-4e3f-b8d3-e24140198dfb GET /v1/drugs/fc285919-2d06-4e3f-b8d3-e24140198dfb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about alteplase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.